Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
ranibizumab (lucentis) (3 trials)
Conjunctival Neoplasms (Phase 1)
Melanoma (Phase 1)
Retinal Diseases (Phase 1)
Trials (3 total)
Trial APIs (1 total)